The last five years have seen an evolution in the management of highgrade astrocytic tumors comparable in scope yet greater in magnitude to that of the prior 40 years. This is thanks to the convergence of three factors: the introduction of an oral agent with antitumor activity beyond the blood-brain barrier and modest systemic toxicity (temozolomide); the demonstration through a well-conducted randomized trial of the superiority of multimodality therapy; and the fact that we now stand on the threshold of additional progress through key advances in translational biology, which, in many cancers, is providing new targets for therapeutic intervention. Long-term follow-up of this study showed that the survival advantage with BCNU wafers was maintained at one, two, and three years, and was statistically significant (p=0.01) at three years compared with placebo, although the absolute number of patients evaluated at this latter timepoint was quite small. Following surgical debulking of the recurrent lesion, an expandable balloon catheter (GliaSite) was placed in the tumor cavity. Although reirradiation of malignant gliomas with the GliaSite system appeared to a report by
of all cancer-related deaths in the US, 1 little if any substantial progress in brain imaging and treatment had been made until the first years of this millennium. Characteristics of high-grade glial tumors compared with other cancers are its unique location, robust invasive and angiogenic capabilities without a significant propensity to metastasize outside of the central nervous system (CNS), and the profound histological and molecular heterogeneity within tumor specimens.
Advances in the Management of Glioblastomas-

Multimodality Strategies
In 2003, a phase III study in 240 newly diagnosed patients with surgically resectable malignant gliomas-including 207 with glioblastoma multiforme (GBM)-compared surgery plus radiotherapy and placebo wafers with surgery plus radiotherapy and the addition of 3.8%
bischloroethyl nitrosourea (BCNU, carmustine) wafers (Gliadel wafers) into the tumor bed. The study demonstrated a modest, albeit significant, prolongation of survival in the latter group (13.9 versus 11.6 months). 2 Long-term follow-up of this study showed that the survival advantage with BCNU wafers was maintained at one, two, and three years, and was statistically significant (p=0.01) at three years compared with placebo, although the absolute number of patients evaluated at this latter timepoint was quite small. 3 Perhaps the most significant advance in the management of glioblastomas emanates from the work of Stupp et al. 4 who, in a safety and efficacy study, randomized 573 patients with newly diagnosed glioblastoma from 85 centers, primarily in Europe, to radiotherapy alone or to radiotherapy plus concomitant temozolomide followed by monthly temozolomide for six cycles. At a median follow-up of 28 months the median survival in the radiotherapy group alone was 12.1 months compared with 14.6 months in the group receiving both treatment modalities (p<0.001). The two-year survival rate was 10.4% with radiotherapy alone versus 26.5% with radiotherapy and temozolomide.
The results of this study produced level 1A evidence for the benefit of this combined modality treatment in initially diagnosed patients, and was Thus, as a next logical step, a fusion of these two prior studies was evaluated in a phase II setting in patients with newly diagnosed, highgrade GBM undergoing resection with BCNU wafer insertion followed by the combination of radiotherapy plus temozolomide. Early interim data have been presented in abstract form. 5 The study end-points include In contrast, the data relating to erlotinib initially appeared somewhat more promising in one study of 31 patients with recurrent glioblastomas, in which six patients achieved a partial response and the six-month PFS was 26%. 14, 15 Of note is that these authors could not determine any correlation between response and EGFR expression or amplification within the tumor specimens. Also, a second phase II study of 30 patients treated with erlotinib failed to result in any objective responses or six-month PFS. 16 Unfortunately, a recent EORTC trial comparing erlotinib with either temozolomide or BCNU in 110 patients with recurrent glioblastoma failed to demonstrate a benefit of the oral targeted therapy with respect to sixmonth PFS or 12-month survival. 17 Optimal dosing of these oral agents, especially while patients are taking enzyme-inducing anti-epileptics or drugs with similar pharmacological effects, may be a significant confounding variable in determining their true clinical efficacy. survival rate at two years compared with only 13.8% in those patients with non-methylated promoter status. 20 Although the preliminary conclusion from this translational study is that MGMT promoter methylation may be predictive of outcome to multimodality treatment in glioblastoma, validation from additional prospective studies is required.
A novel oral protein kinase C inhibitor that initially appeared to have activity in recurrent glioblastoma was enzastaurin. This agent, an oral inhibitor of PKCβ and PI3K/AKT pathways, is well tolerated, possesses antiangiogenic properties in pre-clinical models, and induces tumor cell apoptosis. 21 Enzastaurin is currently being evaluated in phase II trials for Current Management of High-grade Astrocytic Neoplasms-Small but Tangible Progress
MGMT promoter methylation may be predictive of outcome to multimodality treatment in glioblastoma.
the treatment of patients with recurrent high-grade gliomas. Initial results in 87 evaluable patients with recurrent high-grade gliomas showed that enzastaurin treatment was well tolerated and objective radiographic responses were seen in 22% of patients with GBM. The exposure to enzastaurin was significantly lower in patients treated with enzyme-inducing antiepileptic drugs (EIADs). 22 Enzastaurin also appears to be safe in conjunction with radiation therapy and temozolomide in patients with newly diagnosed GBM. 23 GBM is highly angiogenic, and vascular endothelial growth factor (VEGF) is amplified in most GBM tumors. 24 Over the last three years, there has also been an evolution in 
